Stock MPH MEREO BIOPHARMA GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mereo BioPharma Group plc London S.E.

Equities

MPH

GB00BZ4G2K23

Biotechnology & Medical Research

Delayed London S.E.
Other stock markets
 		5-day change 1st Jan Change
- GBX -.--% Intraday chart for Mereo BioPharma Group plc -10.17% -.--%
Apr. 26 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Apr. 24 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48.46 176.7 128.5 72.39 254.1 308 - -
Enterprise Value (EV) 1 64.53 171.2 50.96 27.14 254.1 179.5 165.9 308
P/E ratio - -1.09 x 51.6 x -10.3 x -45.4 x -293 x -59.5 x -34.4 x
Yield - - - - - - - -
Capitalization / Revenue - - 3.52 x - 25.4 x 11.2 x 24.6 x 295 x
EV / Revenue - - 1.4 x - 25.4 x 6.53 x 13.3 x 295 x
EV / EBITDA - -4,758,884 x - - - - - -
EV / FCF - - - - - -14.1 x -7.24 x -11.8 x
FCF Yield - - - - - -7.08% -13.8% -8.48%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 19,592 67,495 108,655 116,734 139,996 140,024 - -
Reference price 2 2.474 2.618 1.183 0.6201 1.815 2.200 2.200 2.200
Announcement Date 6/15/20 3/31/21 3/31/22 3/28/23 3/27/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 36.46 - 10 27.5 12.5 1.045
EBITDA - -35.97 - - - - - -
EBIT 1 -39.52 -37.57 -20.94 -43.57 -28.42 -38.03 -43.02 -44.55
Operating Margin - - -57.42% - -284.16% -138.29% -344.2% -4,263.35%
Earnings before Tax (EBT) 1 -41.12 -166.4 14.24 -36.09 -30 -29.48 -33.17 -44.55
Net income 1 -34.84 -163.6 12.72 -34.2 -29.47 -8.265 -28.71 -44.55
Net margin - - 34.9% - -294.66% -30.06% -229.7% -4,263.35%
EPS 2 - -2.410 0.0229 -0.0600 -0.0400 -0.007500 -0.0370 -0.0640
Free Cash Flow 1 - - - - - -12.71 -22.92 -26.11
FCF margin - - - - - -46.21% -183.36% -2,498.33%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 6/15/20 3/31/21 3/31/22 3/28/23 3/27/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - 36.46 - - - - - - 7.128 2.872 12.5 15 - -
EBITDA - - - - - - - - - - - - - - - -
EBIT -21.14 -16.69 -20.88 -0.204 -10.37 -10.37 -20.73 - -21.81 -21.76 -9.909 -18.51 -18.6 -19.43 - -
Operating Margin - - - -0.56% - - - - - - -139.02% -644.39% -148.8% -129.54% - -
Earnings before Tax (EBT) -22.44 -126.1 -40.35 10.9 - - 3.337 - -19.89 -16.2 -11.94 -18.06 -14.6 -14.88 -15 -15
Net income -18.62 -124.6 -39.01 12.09 - - 0.637 - -19.16 -15.04 -11.03 -18.44 -5.05 -3.24 -15 -15
Net margin - - - 33.15% - - - - - - -154.74% -641.92% -40.4% -21.6% - -
EPS - - -0.3500 0.0223 -0.1700 -0.1700 0.000620 - -0.0300 -0.0300 -0.0200 -0.0200 -0.008500 -0.003500 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 6/15/20 9/29/20 3/31/21 11/2/21 3/31/22 3/31/22 3/31/22 11/2/22 11/2/22 3/28/23 9/7/23 3/27/24 - - - -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 16.1 - - - - - - -
Net Cash position 1 - 5.53 77.5 45.2 - 129 142 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -12.7 -22.9 -26.1
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.02 0.02 0.54 0.01 - 1 3 11
Capex / Sales - - 1.47% - - 3.64% 24% 1,052.63%
Announcement Date 6/15/20 3/31/21 3/31/22 3/28/23 3/27/24 - - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Mereo BioPharma Group plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.2 GBP
Average target price
4.573 GBP
Spread / Average Target
+107.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MREO Stock
  4. MPH Stock
  5. Financials Mereo BioPharma Group plc